# Vascular Effects of SGLT2i in Non-diabetic CKD

> **NCT07060417** · PHASE2 · NOT_YET_RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 52 (estimated)

## Conditions studied

- Non-diabetic Chronic Kidney Disease

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07060417
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-09-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07060417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07060417, "Vascular Effects of SGLT2i in Non-diabetic CKD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07060417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*